Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quaratusugene ozeplasmid - Genprex

Next Previous
Drug Profile

Quaratusugene ozeplasmid - Genprex

Alternative Names: CNVN 202; DOTAP Chol-TUSC2 Liposomal Complex; DOTAP-Chol-fus1; DOTAP-Cholesterol-Fus1 liposome complex; FUS1 cancer gene therapy; GPX 001; INGN-401; ONC-001; ONC-002; ONC-003; ONC-004; Oncoprex; REQORSA; TUSC2 immunogene therapy; TUSC2-nanoparticles

Latest Information Update: 28 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Genprex; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; TUSC2 protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Small cell lung cancer
  • Preclinical Glioblastoma; Mesothelioma
  • Discontinued Triple negative breast cancer

Most Recent Events

  • 28 Jun 2026 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Monotherapy) in USA (IV)
  • 22 Jun 2026 Genprex receives notice of allowance for Quaratusugene ozeplasmid in the Canada
  • 29 May 2026 Pharmacodynamics data from a phase I/II Acclaim 1, Acclaim 2 and Acclaim 3 trial in Lung cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top